Johnson & Johnson Offers Stability Despite Recent Underperformance

This article mentions Johnson & Johnson (NYSE:JNJ) as the stock being discussed. The author's recommendation is to buy this stock for portfolios with a lower risk tolerance.

The author's core argument is that despite recent challenges, Johnson & Johnson is attractively valued and well-positioned for long-term growth and increasing shareholder returns. They highlight the company's AAA-rated balance sheet, its mix of growth and value, and its ability to protect investors from market turmoil.

Key information and data include the underperformance of JNJ shares compared to the S&P 500, the uncertainty surrounding baby powder lawsuits, the company's future growth opportunities in MedTech and Pharmaceuticals, its commitment to R&D and innovation, and its shareholder distribution strategy, including a 3.0% dividend yield. The article also discusses the company's valuation and suggests that it may be trading below its fair value.